Neumann P W, Benning B J, Robinson D G, Gilmore N, O'Shaughnessy M V
CMAJ. 1986 Sep 1;135(5):477-80.
More than 25 000 serum specimens have been tested for antibody to human T-lymphotropic virus type III (HTLV-III) at the Laboratory Centre for Disease Control, Ottawa, since August 1984. In 1985 the prevalence rates of antibody positivity among selected risk groups were as follows: patients with Kaposi's sarcoma, 77%; patients with acquired immune deficiency syndrome (AIDS) or AIDS-related complex (ARC), 66%; patients with hemophilia, 65%; symptomatic homosexual men, 48%; cohabitants of patients with AIDS, ARC or antibody to HTLV-III, 24%; and intravenous drug abusers, 13%. No case of accidental parenteral exposure has resulted in seroconversion. Eight cases of AIDS, all in antibody-positive patients, have been associated with blood transfusions. A testing protocol based on risk-group information is proposed for diagnostic laboratories.
自1984年8月以来,渥太华疾病控制实验室中心已对超过25000份血清样本进行了人类嗜T淋巴细胞病毒III型(HTLV-III)抗体检测。1985年,特定风险人群中的抗体阳性患病率如下:卡波西肉瘤患者为77%;获得性免疫缺陷综合征(AIDS)或艾滋病相关综合征(ARC)患者为66%;血友病患者为65%;有症状的同性恋男性为48%;AIDS、ARC或HTLV-III抗体阳性患者的同居者为24%;静脉注射吸毒者为13%。没有一例意外的非肠道接触导致血清转化。8例艾滋病病例均为抗体阳性患者,均与输血有关。建议诊断实验室采用基于风险人群信息的检测方案。